2. Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) receives second place for its rare-disease commercial momentum. Second-quarter 2026 net product sales reached $176.2 million, compared with $127.8 million a year earlier, representing approximately 38% growth. LIVMARLI sales increased 46% to $128.7 million, while its bile acid medicines generated $47.5 million, up 20%.
The combination of an established lead product and additional marketed medicines gives the business more substance than a development-only biotechnology company. Management raised its full-year net product sales guidance to $680 million–$700 million.
Pipeline progress remains a source of uncertainty. In its August update, Mirum disclosed that the FDA recommended a Phase 3 study for volixibat in one indication, with further discussions planned before a potential application. Quarterly operating expenses also exceeded revenue.
Ranking rationale
Strong product growth and multiple commercial assets support second place, although development spending and regulatory uncertainty matter. Its approximately $5.2 billion market capitalization makes it the clearest size exception.
